Additional doses of COVID-19 are recommended for immunocompromised patients, especially for transplant recipients who are not immune to coronavirus infection, experts say. BMJ today.
The findings underscore the importance of additional doses of COVID-19 vaccine to protect people with weakened immune systems.
It is already known that after immunization, people with weakened immunocompromised immune systems are less able to fight off infections, such as the flu, than people with immunocompetent immunity. Little is known about the response to COVID-19 injection, especially mRNA prevention.
Vaccination after infection or vaccination-priming the immune system to fight a specific virus – called a seroconversion.
To address this knowledge gap, researchers in Singapore analyzed 82 results I noticed reading compare the efficacy of COVID-19 vaccine in individuals who are undernourished and immunocompromised.
Of these studies, 77 (94%) used the mRNA vaccine, 16 (20%) vaccinated against the virus, and 4 (5%) killed the entire vaccine. A total of 63 studies were estimated to be at low risk of bias and 19 at moderate risk of bias.
After a single dose of COVID-19 vaccine, it was found that the reduction in viral load among the immunological groups, excluding people with HIV, was significantly reduced.
The fraction is nearly half as high as in patients with leukemia, inflammatory bowel disorders (e.g. rheumatoid arthritis and psoriasis) and epilepsy (acute myocardial infarction) compared with immunosuppressive control, while recipients of organ transplants were 16 times less likely to relapse.
After the second trimester, seroconversion was significantly increased in patients with leukemia, inflammatory bowel disease and acute myocardial infarction, but decreased significantly in transplant recipients, with only a third successfully reversible. .
Continuing review of 11 studies showed that a third of COVID-19 mRNA treatment was associated with variability among cancer vaccines, leukemiaand inflammatory bowel disease, although the response varies among recipients and there is no published evidence of the effect of a third group in people living with HIV.
Of the immunosuppressive groups studied, antibody levels (titres) were also lower than that of the immune system.
Researchers have shown several limitations. For example, the combined studies were observational and used different meanings of seroconversion. What’s more, the researchers could not rule out the possibility that certain unpredictable factors, such as age and soil conditions, could affect their results.
However, the use of rigorous measures of combining the study with a fixed value and value of the study suggests their end result is strong.
“Actions aimed at immunized patients, including a third, should be done,” they said.
Efficacy of covid-19 vaccine in chronically ill patients: routine review and meta-analysis, BMJ, DOI: 10.1136 / bmj-2021-068632
British Medical Journal
hintStudies suggest additional doses of COVID-19 vaccine for infected patients (2022, March 2) were recovered 2 March 2022 from https://medicalxpress.com/news/2022-03-additional-covid-vaccine- doses-immunocompromised.html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.
Study suggests additional COVID-19 vaccine doses for immunocompromised patients Source link Study suggests additional COVID-19 vaccine doses for immunocompromised patients